Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G for Terns Pharmaceuticals Inc Common Stock (TERN).
- Disclosed ownership: 5.2%.
- Date of event: 30 Sep 2025.
VANGUARD GROUP INC - 30 Sep 2025 SCHEDULE 13G Report for Terns Pharmaceuticals Inc Common Stock (TERN)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Symbol
- TERN
- Shares outstanding
- 87,522,399 shares
- Disclosed Ownership
- 4,559,917 shares
- Ownership
- 5.2%
- Form type
- SCHEDULE 13G
- Filing time
- 31 Oct 2025, 11:31:28 UTC
- Date of event
- 30 Sep 2025
- Next filing
- 27 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 5.2% ownership in Terns Pharmaceuticals Inc Common Stock (TERN) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 31 Oct 2025, 11:31.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 5.2% | 4,559,917 | 0 | 414,169 | Ashley Grim | Head of Global Fund Administration |